Canine parvovirus-like particles, a novel nanomaterial for tumor targeting
Pratik Singh¹,², Giuseppe Destito¹,²,⁴, Anette Schneemann¹,³ and Marianne Manchester*¹,²

Address: ¹Center for Integrative Molecular Biosciences, The Scripps Research Institute, La Jolla, CA 92037, USA, ²Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA, ³Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA and ⁴Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi Magna Graecia di Catanzaro Campus Universitario di Germaneto, Catanzaro, ITALY

Email: Pratik Singh - prasingh@scripps.edu; Giuseppe Destito - giuseppe@scripps.edu; Anette Schneemann - aschneem@scripps.edu; Marianne Manchester* - marim@scripps.edu

* Corresponding author

Abstract
Specific targeting of tumor cells is an important goal for the design of nanotherapeutics for the treatment of cancer. Recently, viruses have been explored as nano-containers for specific targeting applications, however these systems typically require modification of the virus surface using chemical or genetic means to achieve tumor-specific delivery. Interestingly, there exists a subset of viruses with natural affinity for receptors on tumor cells that could be exploited for nanotechnology applications. For example, the canine parvovirus (CPV) utilizes transferrin receptors (TfRs) for binding and cell entry into canine as well as human cells. TfRs are over-expressed by a variety of tumor cells and are widely being investigated for tumor-targeted drug delivery. We explored whether the natural tropism of CPV to TfRs could be harnessed for targeting tumor cells. Towards this goal, CPV virus-like particles (VLPs) produced by expression of the CPV-VP2 capsid protein in a baculovirus expression system were examined for attachment of small molecules and delivery to tumor cells. Structural modeling suggested that six lysines per VP2 subunit are presumably addressable for bioconjugation on the CPV capsid exterior. Between 45 and 100 of the possible 360 lysines/particle could be routinely derivatized with dye molecules depending on the conjugation conditions. Dye conjugation also demonstrated that the CPV-VLPs could withstand conditions for chemical modification on lysines. Attachment of fluorescent dyes neither impaired binding to the TfRs nor affected internalization of the 26 nm-sized VLPs into several human tumor cell lines. CPV-VLPs therefore exhibit highly favorable characteristics for development as a novel nanomaterial for tumor targeting.

Background
Conventional chemotherapy for treating cancer is non-selective and therefore associated with toxic side effects, limiting a drug's therapeutic index [1-4]. Targeted delivery of drugs is ideal in order to enhance therapeutic benefit as well as reduce systemic toxicity. Recently the development of novel methods to achieve specific tumor targeting has received significant focus [5,6]. Strategies investigated towards this goal include "smart" tissue-specific particles such as liposomes [7], antibodies [8,9], viral particles [10-
and dendrimers [13] that are comprised of targeting moieties and cytotoxic drugs.

Currently virus-based nanoparticles (VBNPs) are being extensively investigated for nanobiotechnology applications [12,14]. Many viral particles are in the nanometer size range and are naturally uniform in size because of the structural constraints on capsid assembly. An increasing number of three-dimensional virus structures known to atomic resolution paved the way for derivatization of VBNPs with dyes, metals, peptides, proteins, and small molecules and is being explored for generating novel nanomaterials. In the last decade several VBNPs have been examined for diverse applications such as templates for material synthesis, platforms for polyvalent display, electronic components, and drug targeting [14-19]. Typical characteristics for a VBNP platform qualification include knowledge about its crystal structure, ability to produce in substantial quantities, stability in a wide range of pH, and suitability for genetic manipulation as well as chemical bioconjugation. Viruses and virus-like particles (VLPs) that have been developed for nanotechnology purposes include bacteriophages (M13 and MS2 [16,20]), plant viruses (cowpea mosaic virus (CPMV), cowpea chlorotic mottle virus (CCMV) and tobacco mosaic virus(TMV) [15,18,21,22]), an insect virus (flock house virus [23]), and animal viruses (adenovirus, polyoma virus [24,25]). While infectious plant viral particles can be produced in large quantities, generating substantial amounts of most animal viruses in cell culture systems is not economical. However, production of VLPs in adequate quantities has been achieved by expression of virus capsid proteins in heterologous systems (insect cells, yeast, and bacteria). VLPs are generally found to be structurally identical to native virus particles and more importantly are non-infectious. Viral particles are also being explored as tumor targeting agents. Since most of the established VBNPs do not have any specificity for tumor cells and therefore need to be either genetically or chemically modified in order to achieve targeted delivery. These targeting strategies are typically not as efficient when compared to the natural cell receptor targeting potential of a virus.

In this study we characterized canine parvovirus (CPV)-VLPs as a potential nanomaterial for tumor targeting purposes. CPV, a viral pathogen of canids (dogs) belongs to the family *parvoviridae* [26]. The infectious agent is an icosahedral (T = 1), non-enveloped virus encapsidating a single stranded DNA of about 5 kb and shows an average diameter of 26.4 nm. The viral DNA encodes three polypeptides VP1, VP2 and VP3 that are generated by alternative splicing of viral mRNA. The crystal structure of the virion revealed that a full (DNA-containing) capsid is composed of 60 subunits, primarily of the VP2 subunits (64 kDa) and a few VP1 and VP3 subunits. While empty
capsids contain mostly VP2 subunits along with a minor amount of VP1 subunits but lack VP3 subunits [26]. Each subunit is made up of a central ‘jelly roll’ anti-parallel β-barrel core with elaborate loops between the β-strands (Figure 1A) [26]. Generation of CPV-VLPs in both mammalian cells and insects cells by expressing only the VP2 gene has been described previously [27]. The transferrin receptor (TfR) on canine cells serves as a cellular receptor for the native CPV [28]. Interestingly, infectious CPV particles were also found to bind and enter human cells utilizing TfRs, however, subsequent steps in the replication cycle did not appear to be supported [28].

Transferrin is a circulatory iron carrier protein that is in great demand particularly during cellular growth and proliferation [29]. Since iron is also required by rapidly dividing cancerous cells, a significant upregulation of transferrin receptor expression is seen in a wide variety of tumor cells. Indeed, analysis of TfR expression revealed approximately 10^5 or more receptors per cell in several breast cancer cell lines (including MDA-MB-231) [30], HeLa (human cervical carcinoma) [31], HT-29 (human colon carcinoma cells) [32], K562 (human erythroleukemia cells) [31,33] and pancreatic tumor cells [34] compared to a few or often undetectable TfR levels in normal cells [35]. Therefore tagging a drug or image contrast agent to transferrin for specific delivery to tumor cells emerged as a promising strategy and is being widely explored for tumor-targeted delivery [35,36]. Thus CPV-VLPs that bind to human TfRs may hold an advantage over other viral nanoparticles for tumor-specific delivery.

In this study we examined the suitability of CPV-VLPs for tumor-targeting applications such as chemical modification with small molecules and capability to deliver those molecules to the tumor cells. CPV-VLPs produced in a baculovirus expression system were analyzed for the accessibility and chemical reactivity of capsid surface-exposed lysines for derivatization with fluorescent dye molecules. Binding and internalization of dye-derivatized CPV-VLPs in various human tumor cells was investigated.

**Results and discussion**

For generation of CPV-VLPs, a recombinant baculovirus expressing the full length CPV-VP2 gene (encoding 584 amino acids) under the control of the polyhedrin promoter was utilized to infect insect cells as described previously [27]. In this study, however, instead of Sf-9 cells we utilized insect T.ni cells for production of VLPs as they are known for enhanced protein production. T.ni cells infected with recombinant baculovirus were harvested at different time points (daily from between one through five days) to optimize the yield of CP-V-VLPs. An incubation length of 72–96 hrs post-infection was found to be optimal for maximizing the yield. The VLP yields ranged from 0.5 to 2 mg/liter of infected T.ni cell culture. Harvest of cells before 48 hrs or after 5 days post-infection reduced the VLP yield to less than 50% of a 3–4 day harvest. While early harvest suffered from inefficient infection, late harvest presumably leads to cell lysis releasing VLPs that seem to be vulnerable to cell- or baculovirus-derived proteases (data not shown). It was previously shown that although a large amount of CPV-VP2 protein could be expressed within Sf-9 insect cells, a portion of VP2 fails to assemble into VLPs [27]. During a native parvovirus infection, approximately 50% of the assembled capsids were found to be empty (non-infectious) and composed primarily of VP2 subunits with a few VP1 subunits [26]. Since the VP2 protein alone was expressed in the current study, a co-expression of VP2 and VP1 in the baculovirus expression system may enhance the assembly process and thereby improve the yield of CPV-VLPs. Closely related porcine parvovirus-VLPs appear to assemble more efficiently than CPV in the baculovirus expression system as their yields were substantial, approximately 120 mg/liter of culture in a bioreactor [37]. VLPs of polyoma virus [38], hepatitis B virus surface antigen [39], hepatitis delta virus [40] and CCMV [41] have also been produced in large quantities in a yeast expression system that may be useful for generating CPV-VLPs.

To evaluate whether CPV-VLPs could be efficiently derivatized by chemical methods as has been performed for several viral nanoparticles [14], the location of surface lysines on CPV-VLPs was identified based upon a structural model of CPV using the radial distance and solvent accessibility surface area parameters in the VIPER database as described in the methods. Based on the analyses, lysines at positions 89 and 312 are highly accessible while those...
at positions 163 and 387 are moderately accessible and those at positions 570 and 575 on the particle surface are accessible to lesser extent (Figure 1B). Using this model, two (maximum of 6) lysines of the twenty lysines per VP2 subunit, or 120 (maximal of 360) lysines per CPV-VLP particle could theoretically be accessible on the capsid surface for bioconjugation. However, the reactivities are known to vary from their predicted accessibility based upon the local chemical environment of the lysine residue on the capsid surface [15]. Surface accessible lysines on the capsid and on a single subunit of VP2 are depicted in a space filling model in Figure 2. Immediately following purification, the CPV-VLPs were examined for reactivity and conjugation to the lysines by exposure to NHS-Oregon Green 488 (OG-488). In most cases, using 100 molar equivalents of OG-488 dye molecules per VP2 subunit in the VLP preparation, an average of 45 lysines/particle were addressed. Exposure to 200 molar equivalents of the dye per VP2 subunit resulted in an average of 100 derivatized lysines/particle. Further increase in the dye equivalents did not appear to enhance CPV-VLP labeling (data not shown). Initially, the virus labeling was carried out in a phosphate buffer (0.1 M potassium phosphate) similar to dye derivatization of CPMV [15]. The CPV-VLP particles, although stable in phosphate buffer, could not withstand the presence of additional 10% DMSO and a dye, which caused disassembly of the VLPs into subunits. In contrast CPMV particles are known to withstand such labeling environment [15]. Performing dye labeling of CPV-VLPs in PBSE buffer, or in phosphate buffer containing 150 mM sodium chloride stabilized the particles (data not shown).

To characterize the CPV-VLPs from the infected T.ni cell culture, particles were centrifuged in a 10–40% sucrose gradient. The VLPs formed two bands visible about the middle of the tube (data not shown). A hazy smeared upper band presumably represented a mixture of empty
particles (lacking nucleic acids) and particles with variable amounts of nucleic acids. The lower faint band we hypothesized was comprised of particles with a definite amount of randomly packaged cellular nucleic acid material. The proportions of these bands varied greatly over each preparation. The packaging of non-specific cellular nucleic acids into VLPs during baculovirus expression has been described [42]. The smeared VLP bands in the gradient also suggested VLP preparation has packaged variable amounts of nucleic acids that are most likely random cellular RNA since the particles assemble in the cytoplasm (data not shown). Gradient purified VLP preparation was collected and analyzed by SDS-PAGE for presence of viral coat protein and to evaluate sample purity. The gel revealed a 62 kDa protein corresponding to the known molecular weight of CPV-VP2 protein (Figure 3B) with no obvious degradation products or impurities. The difference in VP2 gene product to an expected 64 kDa is presumed to be due variation in gel mobilities of proteins. Similar to unlabeled particles, CPV-VLP particles labeled with the dye OG-488 when separated on the gradient revealed a smeared top band and another band about the

Figure 4
Capsid stability and morphology of CPV-VLPs. A and B. Size exclusion chromatography (SEC) of CPV-VLPs. Sucrose gradient purified samples were passed through a Superose6 size exclusion column. Absorbance values recorded at 260 nm (for nucleic acids), 280 nm (for protein) and 496 nm (for OG-488 dye) are shown on the y-axis. The elution profile from the column in ml is shown on x-axis. Panel A shows SEC of freshly purified CPV-VLPs and panel B shows SEC of CPV-VLPs labeled with OG-488 dye following 1 week of storage at 4°C. C and D. Electron micrographs of CPV-VLPs. CPV-VLPs were deposited onto carbon-coated copper grids and stained with uranyl acetate. The micrographs of (C) full capsids in a freshly purified CPV-VLPs preparation and (D) empty capsids in CPV-VLPs sample after 1 week of storage are shown. Both micrographs were taken at a nominal magnification of 60,000×.
middle of the gradient, similar to that of a native CPV-VLP preparation (Figure 3A left panel). The band appeared fluorescent when exposed to a UV-light source (Figure 3A, right panel). Dye-derivatized CPV-VLPs, when analyzed on SDS-PAGE showed a fluorescent band upon exposure to a UV-light source that migrated at 62 kDa. No difference was observed in the mobility of the dye-derivatized CPV-VP2 subunit protein compared to native CPV-VP2 subunit protein under the SDS-PAGE conditions used, as expected since there are an estimated 1 to 2 molecules of OG-488 dye per VP2 subunit (with approximate increase of about 0.6 to 1.2 kDa; Figure 3B).

The sucrose gradient-purified particles were analyzed by size exclusion chromatography (SEC) for elution volume and absorbance indicative of particle size, intactness and packaged nucleic acid material. SEC of a freshly purified VLP preparation revealed that the absorbance at 260 nm was high compared to absorbance at 280 nm (Figure 4A) suggestive of packaged nucleic acids. With a flow rate of 0.4 ml/min in PBSE buffer (pH 7.4), the particles had elution volume of 11–13 ml on the SEC column. Cowpea mosaic virus particles (approximately 31 nm in diameter) that are routinely used our laboratory showed an elution of 8 to 10 ml in PBSE buffer (data not shown) on the same column suggested that the CPV-VLPs (26 nm-sized) are smaller in size and intact. Disassociated or unassembled subunits and other contaminant proteins showed elution volumes greater than 15 ml. Surprisingly, containment of nucleic acid material within CPV-VLPs was transitory, as the particles were found to be empty after one to two days of storage at 4°C. After a week of storage at 4°C the particles exhibited a lower absorbance at 260 nm indicating lack of nucleic acid material (Figure 4B). Presumably the packaged nucleic acid was hydrolyzed. Finding entirely empty particles immediately following purification was also not uncommon. Although empty, the CPV-VLPs were found to be quite stable in PBSE buffer after several months of storage at 4°C without showing any signs of disassembly. The particle intactness could be confirmed over the SEC column and by transmission electron microscopy (TEM) (data not shown). Analyses of dye-labeled particles on the SEC at 496 nm revealed that the conjugate dye molecules are associated with the intact VLPs (Figure 4B). TEM analyses of purified VLPs supported the observation that the particles were not empty initially following purification. Figure 4C shows the CPV-VLP capsids with an electron-dense core indicating the presence of nucleic acid. In contrast, after 7 days of storage the particles have an electron-opaque core consistent with empty capsids (Figure 4D). Interestingly, expression of coat proteins from the RNA viruses, FHV coat protein [42] or tomato bushy stunt virus [43] in the baculovirus system results in VLPs containing variable amounts of cellular RNA. However, this packaged cellular RNA is not lost upon storage. Presumably, as a DNA-containing virus, the CPV capsid interior has natural affinity for viral single-stranded DNA and therefore lacks the capability to retain any of the non-specifically packaged RNA, resulting in empty particles eventually.

Previous studies have revealed that the native CPV utilizes canine as well as human TfRs to internalize and reach the endosomes in cells [28]. Detailed analyses of CPV capsid
revealed that the Asn residues at positions 93 and 300 on the three fold spike are important in binding to the canine TfRs. Additionally, several residues in the shoulder region (Gly 299, Lys 387, Ala 300, Thr 301, and val 316) also appear to play a role in binding [44]. Based on the CPV-capsid modeling (Figure 1B) the Lys residues at positions 89 and 312 are the most solvent accessible and therefore more likely to be derivatized. In our bioconjugation experiments, attachment of dyes to the Lys 387 residue in some of the subunits cannot be ruled out. However, the role of these residues in CPV binding specifically to human TfRs has not been determined.

Once it was demonstrated that CPV-VLPs could withstand chemical conjugation and remain intact following purification, the dye-labeled CPV-VLPs were investigated for their potential utility to target tumor cells. First we examined the binding and internalization of CPV-VLPs into HeLa tumor cells that over-express TfRs [31] (Figure 5). The internalization of CPV-VLP particles was fairly rapid, occurring within two hours as previously observed with native CPV [28]. Co-localization of the antibodies recognizing CPV-VLPs with Texas red-labeled transferrin confirmed that the VLPs are localized to endosomes following uptake. Confocal image analyses showed approximately 50–60 % co-localization, and the differences seen are likely due to fact that TfN is efficiently recycled while CPV particles are diverted from endosomes to lysosomes, consistent with previous reports [28,45]. Binding to TfRs and clathrin-mediated vesicular trafficking of CPV to endosomes and lysosomes in the cells has been demonstrated previously in HeLa cells and in non-cancerous NLFK cells [28,45]. We next examined whether CPV-VLPs derivatized with OG-488 dye molecules will show a similar cell binding and internalization characteristics. To confirm the TfR specificity, the binding of OG-488-labeled CPV-VLPs to TRVb1 cells (expressing TfR), and TRVb cells (lacking or expressing very low levels of TfR) [46] was investigated. The binding and internalization of dye-labeled CPV-VLPs was observed only in the TRVb1 cells but not in TRVb cells (Figure 6) confirming that binding and internalization is TfR-mediated. Thus the TfR-specific internalization of OG-488 labeled CPV-VLPs is similar to the native CPV-virions, in agreement with an earlier report [28]. Since CPV-VLPs could efficiently enter HeLa tumor cells and the dye-labeled CPV-VLPs demonstrated TfR specificity, we then examined binding and internalization of OG-488-labeled CPV-VLPs into other human tumor cell lines that are known to over-express TfRs such as HT-29 and MDA-MB231 cells [30,31]. The CPV-VLPs derivatized with OG-488 were taken up by all three cell lines investigated within 2 hours, similar to unlabeled particles in HeLa cells (Figure 7).

Thus we have demonstrated that CPV-VLPs, derivatized with small molecules to the lysines on the capsid surface, retain their targeting for TfRs. Furthermore, CPV-VLPs can withstand the conditions required for chemical modification expanding their utility for conjugation with chemotherapeutic drugs or image contrast agents. Our future efforts are directed towards tumor targeting with dye and drug-labeled VLPs in mouse models of human cancer. Derivatization of CPV-VLPs with chemotherapeutic drugs conjugated via various kinds of endosomal cleavable linkers [8,47] is being investigated for release of the drug specifically into the tumor cell interior. While there are many kinds of nanoparticles in development for tumor targeting [6], VBNPs compared to their peers, exhibit remarkable uniformity and offer precise control over display of molecules. Achieving this level of control over spatial distribution is unparalleled with inorganic or lipid nanomaterial. However, since VLPs are proteinaceous in composition, an immune response by the host is obvious, limiting their usage for repeat administration. Utilizing multiple VLPs or employing polymer coat shielding of particles [48,49] or using altered chimeric particles [50] may address immune clearance issues.

**Conclusion**

CPV-VLPs can be produced in significant quantities in the baculovirus expression system. Optimization of the expression including addition of other regions of capsid proteins or truncated versions of VP2 gene or other systems of protein expression may be useful for further improving the particle yield. Like native CPV, dye-labeled CPV-VLPs specifically bind to TfRs known to be upregu-
lated on a variety of tumor cells. Derivatization of lysine residues on CPV-VLPs with small molecules is feasible under appropriate reaction conditions and does not interfere with the binding and internalization into tumor cells. Together these studies demonstrate the potential for development of CPV-VLPs as a novel virus-based platform for tumor targeted delivery of drugs and image contrast agents.

Materials and methods

Production and purification of CPV-VLPs from insect cells

Recombinant baculovirus production of CPV-VLPs has been previously described [27]. The recombinant virus was a gift of Dr. C. Parrish (Cornell University, Ithaca, New York). Initial stock preparation, plaque purification and determination of plaque forming units (pfu) was performed in Spodoptera frugiperda (Sf-21) cells. For large scale preparations, Trichoplusia ni (T.ni) cells were propagated at 27°C in EX-CELL 401 serum-free medium (JRH Biosciences, Lenexa, KS) supplemented with 2 mM L-glutamine, 100 U/ml of penicillin per ml, and 100 µg/ml of streptomycin. Each liter of culture containing 1 × 10^6 cells/ml was infected with 15 to 20 ml of recombinant virus at a titer of 5 to 8 × 10^6 pfu/ml. Following incubation of infected cells at 28°C and 100 rpm in shaker flask (typically for 72 hrs), cells were harvested by centrifugation at 1500 g for 10 mins. The cells were re-suspended in 100 ml of phosphate buffered saline (PBS) containing 10 mM ethylene diamine tetra acetic acid (EDTA, pH 7.4). The cells were lysed by addition of Triton X-100 to a final concentration of 1% along with 2 mM phenylmethyl sulfonyl fluoride on ice for 10 minutes. The cell debris was pelleted by centrifugation at 10000 g for 30 mins. To the supernatant an equal volume of chloroform/butanol mixture (1:1) was added and stirred for 15 mins at 4°C. The solution was centrifuged at 10000 g for 20 mins. The aqueous supernatant was collected carefully and polyethylene glycol 8000 and sodium chloride were added to a final concentration of 8% and 400 mM respectively. The mixture after stirring for 20 mins at 4°C was centrifuged at 15000 g for 20 mins. The pellet containing the CPV-VLPs was resuspended in 10 ml of PBSE. Following 30 minutes of mixing on a shaker at room temperature, the suspension was centrifuged at 9000 g to remove insoluble debris. The supernatant comprising of the CPV-VLPs was transferred to a tube containing 4 ml of 20% sucrose cushion in PBSE and centrifuged in a 50.2 Ti rotor (Beckman, Fullerton, CA) at 145,000 g for 3 hrs at 4°C. The pellet was resuspended in 1 ml of PBSE and then layered onto a 10–40% sucrose gradient in PBSE, and centrifuged at 207000 g for 2 hrs in a SW41 rotor (Beckman) at 4°C. Bands visible about the mid-point of tube were collected and centrifuged in 50.2Ti rotor at 145000 g for 3 hrs at 4°C. The collected pellet comprising of purified CPV-VLPs was resuspended in PBSE and stored at 4°C. Purified VLP samples were analyzed by sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE), size exclusion chromatography and transmission electron microscopy. The yield of VLPs was quantitated using a Lowry protein assay kit (Pierce, Rockford, IL).

CPV-VLPs denatured in SDS-PAGE sample buffer were separated in a 4–12% bis-tris polyacrylamide gel (Invitrogen, Carlsbad, CA) by employing a 200 V constant current for 35 minutes. The protein bands were visualized by staining with Simply Blue (Invitrogen). For dye-labeled

Figure 7

Binding and internalization of CPV-VLPs labeled with OG-488 into tumor cell lines. Tumor cell lines (A) HeLa, (B) HT-29 and (C) MDA-MB231 were exposed to OG488-labeled CVP-VLPs. The cells were washed, fixed and examined by confocal fluorescence microscopy for internalization of the particles. Scale bar, 25 µm.
virus (see below), following electrophoresis the gel was placed on a UV-light box to visualize fluorescent bands. SEC was carried out on a Superose6 column using an AKTA explorer (Amersham-Pharmacia Biotech, Piscataway, NJ) with a flow rate of 0.4 ml/minute in PBSE buffer (pH7.4).

**CPV-VLP modeling**
The CPV-VLP capsid structure (Figure 1A,B) was obtained from the virus particle explorer database (VIPER) [51]. The model shown was rendered with CHIMERA software [52]. The inset in figure 1A shows a ribbon diagram of a single VP2 protein subunit. The accessible lysines on the capsid surface were determined based on the radial distance of the residue, effective radius and solvent accessible surface area of CPV-VLPs in VIPER database that was originally determined using CHARMM software [53]. The identified surface accessible lysines were then represented in a space filling model of CPV-VLPs designed using Visual Molecular Dynamics software (VMD) [54].

**Dye labeling of CPV-VLPs**
Based on previously published methods for dye labeling of the plant virus CPMV [15], CPV in PBSE was labeled with various molar equivalents of the dye, Oregon green-488 succinimidyl ester (OG-488, Invitrogen). Briefly, OG-488 dye (MW_r = 662.5) was added to 100 or 200 molar equivalents per VP2 subunit (MW_r = 64000) as follows. First the dye was dissolved in dimethyl sulfoxide (DMSO) and then mixed with virus in PBSE to contain not more than 10% of DMSO final concentration. A virus concentration of 2 mg/ml in PBSE was used for all dye labeling reactions. Following overnight incubation at room temperature, hydroxalamine (pH 8.5) was added to a final concentration of 1.5 M to inactivate the dye ester. The dye-labeled virus was sucrose gradient purified as described above. The collected virus band was further dialyzed with 3 exchanges against PBSE. The amount of dye conjugated onto the VLPs calculated as absorbance measured at 496 nm times the molecular weight of virus (64000 x 60) divided by the product of extinction coefficient of OG-488 dye (70000) and concentration of virus in mg/ml. VLPs derivatized with the dye were analyzed by SDS-PAGE, SEC and TEM. The binding and internalization of dye-labeled CPV-VLP in TRVb, TRVb1 and tumor cells was examined by confocal microscopy.

**Cell lines**
Human tumor cell lines, HT-29, HeLa and MDA-MB231 were obtained from American Type Culture Collection (Manassas, VA). HT-29 was maintained in Leibovitz medium (Invitrogen) while HeLa and MDA-MB231 were cultured in modified DMEM (Invitrogen). Chinese hamster ovarian cells TRVb (negative for transferrin receptor expression) and TRVb1 (derived from TRVb cells containing an expression plasmid for human transferrin receptor) have been previously described (gift of Dr. T. Mc Graw, Cornell University) [46] and were maintained in Ham’s F-10 medium (Invitrogen) without or with 0.2 mg/ml of genetin (Invitrogen) respectively. Each of the culture media containing L-glutamine described above was supplemented with 10% fetal bovine serum, and antibiotics penicillin (100 U/ml) and streptomycin (100 µg/ml).

**Confocal and electron microscopy**
Approximately 10,000 cells/well of HeLa cells were plated in a 12-well tissue culture plate containing circular glass cover slips. After overnight incubation, the cells were exposed to either 10 µg/ml of Texas red-labeled transferrin (Invitrogen) or 20 µg/ml of CPV-VLPs or both (for colocalization studies) for 2 hrs at 37°C in media without serum. Following incubation the cells were washed 3 times with media and then fixed with ice-cold 4% paraformaldehyde in PBS (pH 7.4) for 10 mins. After fixing, the cells were washed 3 times with PBS and then treated for 10 mins in PBS containing 0.1% Triton X-100 and 1% bovine serum albumin (permeabilization buffer). The cells were exposed to rabbit anti-CPV antibodies (1:500) diluted in permeabilization buffer for 1 hr at room temperature. The cells were washed three times in PBS and exposed to Alexa-488 labeled goat anti-rabbit antibodies (Invitrogen) at a dilution of 1:2000 in permeabilization buffer for 30 mins at room temperature. The cover slips were washed three times with PBS then quickly with water prior to mounting with Vectashield hard set medium (Vector Laboratories, Burlingame, CA) on glass slides. The cells were examined with a Zeiss Axiocamt Confocal microscope. For experiments with TRVb, TRVb1 and various tumor cells, each of the cell line was exposed to OG488-CPV-VLP under similar conditions as described above. Additionally, TRVb cells were treated with TOTO-3 (Invitrogen) for nuclear staining. Following fixation the cells were washed with PBS and directly visualized by confocal microscopy.

Transmission electron microscopic analyses of CPV-VLPs were performed by depositing 10 µl aliquots of sample onto 100-mesh carbon-coated copper grids for 2 minutes. The grids were then stained with 10 µl of 2% uranyl acetate and visualized under a Philips CM100 electron microscope.

**Authors’ contributions**
PS conceived the study and performed experiments. GD assisted with dye labeling, virus structural modeling and column chromatography analyses. AS assisted with the baculovirus expression system and virus purification. MM provided guidance with the experimental design and manuscript preparation. All authors read and approved the final manuscript.
Acknowledgements
We thank C. Hsu and Dr. W. Ochoa for assistance with electron microscopy. The authors acknowledge the help of Dr. V. Reddy (TSRI) in CPV virus capsid modeling. We appreciate the generous gift of baculovirus recombinant expressing CPV-VP2 protein and TRV1b cells by Drs. C. Parrish and T. McGraw respectively at Cornell University, New York. This work presented in this TSRI manuscript #17725-CB was supported by grants CA112075 and NOI-CO-27181 to M.M. and A.S.

References
1. Fennelly D: Dose intensity in advanced ovarian cancer: have we answered the question? Clin Cancer Res 1995, 1:575-582.
2. Myers CE, Chabner BA: Anthracyclins. In Cancer chemotherapy-principles and practice Edited by: Chabner, B. A., Collins, J. M. Philadelphia, Lippincott; 1990:256-381.
3. Dubowchik GM, Walker MA: Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmac Ther 1998, 83:67-123.
4. Feng SS, Chien S: Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chemical Engineering Science 2003, 58:4087-4114.
5. Hronon-Peggs L, Blanchette JG: Nanoparticle and targeted systems for cancer therapy. Advanced drug delivery reviews 2004, 56:1649-1659.
6. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
7. Medina OP, Zhu Y, Kairerino K: Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004, 10:2981-2989.
8. Doronina SO, Torki BE, Toki BE, Mendelsohn BA, Cerveny C.G, Kotz WA, Moyer DL: Development of potential monomolecular antitubulin conjugates for conjugation therapy. Nat Biotechnol 2003, 21:778-784.
9. Muldoon L.L., Neuwelt EA: BR96-DOX immun conjugate targeting of chemotherapy in brain tumor models. J Neurooncology 2003, 65:517-522.
10. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, Taylor-Robinson AW, Stockley PG: RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Interntumorology 2002, 45:371-380.
11. Abbing A, Blaschke UK, Grein S, Kreischman M, Stark CM, Thies MJ, Walter J, Weigand M, Woith DC, Hess J, Reiser CO: Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem 2004, 279:27410-27421.
12. Pattenden LK, Middelberg AP, Niebert M, Lipin DI: Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 2005, 23(10):523-529.
13. Kuokstis-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR: Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005, 65:5317-5324.
14. Singh P, Gonzalez MJ, Manchester M: Viruses and their uses in nanotechnology. Drug Development Research 2006.
15. Wang Q, Kalderon D, Lin T, Johnson JE, Finn MG: Natural supramolecular building blocks: wild type cowpea mosaic virus. Chem Biol 2002, 9(7):805-811.
16. Peabody DS: A viral platform for chemical modification and multivalent display. J Nanobiotechnology 2003, 1:5.
17. Hooker JM, Kovacs EW, Francis MB: Interior surface modification of bacteriophage MS2. J Am Chem Soc 2004, 126:3717-3719.
18. Basu G, Allen M, Willits D, Young M, Douglas T: Metal binding to cowpea chlorotic mottle virus using terbium(III) fluorescence. J Biol Imag 2003, 8:721-725.
19. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG: Accelerated biochemical conjugation: A practical method for ligation of diverse functional molecules to a polyclonal virus scaffold. Bioconjug Chem 2005, 16(6):1572-1579.
20. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasquale R: Design and validation of a functional ligand display system for receptor targeting. Chemistry & Biology 2004, 11:1081-1091.
21. Chatterji A, Ochoa W, Paine M, Ratna BR, Johnson JE, Lin T: New Addresses on an addressable virus nanopblock: uniquely reactive lys residues on cowpea mosaic virus. Chemistry and Biology 2004, 11:855-863.
22. Chatterji A, Ochoa W, Shamieh L, Salakan SP, Wong SM, Clingon G, Ghosh P, Lint T, Johnson J: Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 2004, 15:807-813.
23. Portney NG, Singh K, Chaudhury, S., Destito G, Schneemann A, Manchester M, Ozkan M: Organic and inorganic nanoparticle hybrids. Langmuir 2005, 21:2098-2103.
24. Henning P, Anderson KM, Fyrholm K, Ali A, Magnusson MK, Nyman PA, Granio O, Odén SS, Boulanger P, Lindholm L: Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther 2005, 12:211-224.
25. Gleiter S, Lile H: Cell-type specific targeting and gene expression using a variant of polyoma VP1 virus-like particles. Biol Chem 2003, 384.
26. Tsao J, Chapman MS, Agbandje M, Keller W, Smith K, Wu H, Luo M, Smith TJ, Rossmann MG, Comans RW, Parrish CR: The three-dimensional structure of canine parvovirus and its functional implications. Science 2003, 302:525-534.
27. Yuan W, Parrish CR: Canine parvovirus capsid assembly and differences in mammalian and insect cells. Virology 2001, 279:546-557.
28. Parker JS, Murphy WJ, Wang D, O’Brien SJ, Parrish CR: Canine and feline paroviruses can use human or feline transferrin receptors to bind, enter, and infect cells. J Virol 2001, 75:3896-3902.
29. Gomme PT, McCann KB, Bertolini. J: Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005, 10:267-273.
30. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993, 156:212-217.
31. Bridges KE, Smith BR: Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J Clin Invest 1985, 76:913-918.
32. Becker A, Riefler B, Ebert B, Sukowski U, Rinneberg H, Semmler W, Licona K: Macromolecular contrast agents for optical imaging of tumors: comparison of indocarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 2000, 72:234-241.
33. Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H, Fuji S, Kawasaki M, Itoh Y, Koshiba Y, Koga Y, Kato J, Sakamaki S, Niitsu Y: In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugated. FASEB J 2000, 14:208-218.
34. Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J: Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 2004, 40:1418-1422.
35. Qian Z, Li H, Sun H, Ho K: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharm Rev 2002, 54:561-587.
36. Hagemann-Savellano D, Bos E, Blonder C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters JP, Basilion JP: The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003, 5:495-506.
37. Maranga L, Rueda P, Antonis AF, Yela C, Langeveld J, Cassal JI, Carrozza MJ: Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 2002, 59:45-50.
38. Sanauskas K, Bulavaite A, Hale A, Jin L, Knowles WA, Gvedilaita A, Dargieviciute D, Zvirbliene A, Staniulis J, Brown DW, Ulrich R: Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 2002, 45:308-317.
39. Li HZ, Geng H, Liu X, Ma YB, Sun MS, Dai CB: Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles. Chin Med J 2004, 19:78-83.
40. Wu HL, Chen PJ, Mu JJ, Chi WK, Kao TL, Hwang LH, Chen DS: Assembly of hepatitis delta virus-like empty particles in yeast. Virology 1997, 236:374-381.
41. Brumfield S, Willis D, Tang L, Johnson JE, Douglas T, Young M: Heterologous expression of the modified coat protein of Cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. *J Gen Virol* 2004, 85:1049-1053.

42. Krishna NK, Marshall D, Schneemann A: Analysis of RNA packaging in wild-type and mosaic protein capsids of flock house virus using recombinant baculovirus vectors. *Virology* 2003, 305:10-24.

43. Hsu C, Singh P, Ochoa W, Manayani Dj, Schneemann A, Reddy V: Characterization of polymorphism displayed by the coat protein mutants of tomato bushy stunt virus. *Virology* 2006; manuscript accepted.

44. Parker JS, Parrish CR: Canine parvovirus host range is determined by the specific conformation of an additional region of the capsid. *J Virol* 1997, 71:9214-9222.

45. Suikkhonen S, Saajarvi K, Hirsimaki J, Valilehto O, Reunanen H, Viikinen-Ranta M, Vuento M: Role of recycling endosomes and lysosomes in dynein-dependent entry of canine parvovirus. *J Virol* 2002, 76:4401-4411.

46. McGraw TE, Greenfield L, Maxfield FR: Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor. *J Cell Biol* 1987, 105:207-214.

47. Dharap SS, Wang Y, Chandra P, Khandare JJ, Qiu B, Gunaseelan S, Sinik P, Stein S, Farmanfarmaian A, Minko T: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. *Proc Natl Acad Sci U S A* 2003, 102:12962-12967.

48. Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW: Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. *Gene Ther* 2004, 11:1256-1263.

49. Raja KS, Wang Q, Gonzalez Mj, Manchester M, Johnson JE, Finn MG: Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. *Biomacromolecules* 2003, 4:472-476.

50. Netter Hj, Woo WP, Tindle R, Macfurlan RI, Gowans EJ: Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. *Vaccine* 2003, 21:2692-2697.

51. Reddy VS, Natarajan P, Okerberg B, Li K, Damodaran KV, Morton RT, Brooks CL, Johnson JE: Virus Particle Explorer (VIPER), a website for virus capsid structures and their computational analyses. *http://viperdb.scripps.edu*. *J Virol* 2001, 75:11943-11947.

52. *http://www.chimera.org*.

53. Brooks B, Bruccoleri R, Olafson D, States D, Swaminathan S, Karplus M: CHARMM: a program for macromolecular energy, minimization and dynamics calculation. *J Comp Chem* 1983, 4:183-217.

54. *http://www.ks.uiuc.edu/Research/vmd/.*

---

**Publish with BioMed Central and every scientist can read your work free of charge**

*“BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime.”*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:

[http://www.biomedcentral.com/info/publishing_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)